<DOC>
	<DOCNO>NCT02188745</DOCNO>
	<brief_summary>Before anti-estrogens tamoxifen develop treat estrogen receptor ( ER ) -positive breast cancer , high-dose estrogen therapy use . This seem counterintuitive since anti-estrogens block ER function , estrogens increase ER function , therapy effective similar extent treatment metastatic ER+ breast cancer . Estrogen therapy effective cancer develop resistance anti-estrogens , likely cancer adapt grow without ER function , restore ER function ( estrogen ) damaging cancer cell . In patient ER+ breast cancer become resistant anti-estrogens , treatment estrogen 17b-estradiol induces tumor response . Furthermore , 17b-estradiol-sensitive tumor eventually become resistant 17b-estradiol , switch back anti-estrogen therapy often effective . These observation suggest cancer alternate anti-estrogen-sensitive 17b-estradiol-sensitive state . The investigator hypothesize treatment alternate 17b-estradiol / anti-estrogen therapy define 8-week / 16-week schedule effectively prevent cancer growth continuous treatment either type therapy patient metastatic anti-estrogen-resistant ER+ breast cancer .</brief_summary>
	<brief_title>ER Reactivation Therapy Breast Cancer</brief_title>
	<detailed_description>Metastatic breast cancer rarely cure current therapy . ER+ breast cancer ultimately become resistant available anti-estrogens . Response rate estrogens similar anti-estrogens metastatic setting . Given ER+ breast cancer often responsive anti-estrogens estrogen , alternate anti-estrogen/estrogen therapy may effective continuous treatment either type agent . Anecdotal evidence indicate strategy alternate therapy effective patient . Preclinical evidence suggest anti-estrogen-resistant ER+ breast cancer sensitize anti-tumor effect estrogen . Such cell harbor subpopulation ultimately regain ability grow presence estrogen , revert anti-estrogen-sensitive state . The investigator formally test whether alternate 17b-estradiol/anti-estrogen therapy effective management anti-estrogen-resistant metastatic ER+/HER2- breast cancer , identify molecular biomarkers predict tumor response 1 ) 17b-estradiol 2 ) alternate 17b-estradiol/anti-estrogen therapy . If successful , study would present novel strategy manage metastatic ER+/HER2- breast cancer pre-emptively switch therapy prior disease progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Women ≥18 year age clinical stage IV ER+/HER2 breast cancer , locally recurrent ER+/HER2 disease amenable therapy curative intent . 2 . Most recent treatment must Tamoxifen , Raloxifene , Toremifene , Aromatase Inhibitor ( letrozole , anastrozole , exemestane ) , patient must ontreatment time recurrence/progression undergo tumor biopsy , perform standard care . Treatment Exemestane plus Everolimus ( Afinitor® ) , hormonal therapy combination CDK inhibitor , experimental therapeutic , prior recent therapy allow . Any number prior line antiestrogen therapy permissible . One line prior chemotherapy advanced/metastatic disease permissible . 3 . Histologic documentation ERhigh/HER2negative breast cancer core needle , fine needle aspiration , incisional biopsy ≥1 site ( ) metastatic locally advanced disease perform standard care within 2 month prior assessment eligibility study participation ( except , note , patient boneonly metastatic breast cancer ) . 1 . ERhigh status define ER stain immunohistochemistry ≥50 % malignant cell nuclei intensity ≥2+ scale 03+ . These criterion equivalent Allred score ≥6 . 2 . HER2low status define immunohistochemistry score 01+ , FISH ratio &lt; 2 IHC 2+ IHC do . 3 . Excess tumor tissue biopsy must available molecular analysis . This include tumor tissue sufficient make ≥10 fivemicron section ; tumor tissue prefer . 4 . Frozen tumor tissue ( acquire clinically indicated tumor biopsy ) strongly prefer research analysis ( available ) . Tumor tissue procure 1214 day 17b estradiol therapy part repeat research biopsy ( optional ) process ( FFPE frozen ) manner tissue acquire baseline . 5 . Patients boneonly metastatic disease history ER+/HER2 primary breast cancer eligible , bone biopsy require , provide primary cancer consistent abovedescribed ER HER2 criterion . 4 . Patient must candidate treatment 17bestradiol aromatase inhibitor . 5 . If recent therapy adjuvant setting , recurrencefree interval ( time initiation adjuvant antiestrogen therapy clinical evidence disease recurrence ) must least 2 year . If recent therapy advanced/metastatic setting , progressionfree interval must least 4 month . 6 . Patient must postmenopausal base either history oophorectomy , least one year amenorrhea . An elevated serum gonadotropin level use confirm menopausal status subject &lt; 1 year amenorrhea . 7 . Routine clinical staging , include either PET/CT , CT ( CAP ) bone scan . 8 . Patient must capable willing provide inform write consent study participation . 9 . The following laboratory value must confirm eligibility , within 28 day prior initiation study therapy : Hematology panel hemoglobin &gt; 9 g/dL white blood cell ( WBC ) count ( ≥ 2,000/UL ) platelet count ≥ 75,000/UL Serum biochemistry/metabolic panel creatinine ≤ 1.5 x upper limit normal ( ULN ) total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ALT AST ≤ 3.0 x upper limit normal ( ULN ) For patient liver metastasis : &lt; 5 x upper limit normal ( ULN ) 1 . Treatment fulvestrant within 4 month prior study enrollment . 2 . Any concurrent systemic anticancer treatment , include conventional chemotherapeutic agent biological agent , study period . Agents ameliorate bone turnover ( e.g. , bisphosphonates , denosumab ) permit . 3 . Any investigational cancer therapy last 28 day . 4 . Known CNS disease , unless clinically stable ≥ 3 month . 5 . History follow : deep venous thrombosis pulmonary embolism stroke acute myocardial infarction congestive heart failure previous malignancy treat curative intent , estimate *recurrence risk ≥30 %</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>ER+</keyword>
	<keyword>Estrogen therapy</keyword>
	<keyword>Estradiol therapy</keyword>
</DOC>